Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL911807

Cc1ccc(OC2CC3CCCC(C2)N3)cc1F.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.46
SLC6A4 P31645 16/20 0.44
SLC6A2 P23975 13/20 0.44
SLC6A3 Q01959 12/20 0.44
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
CHRNA1 P02708 1/20 0.40
CHRNG P07510 1/20 0.40
ITGA5 P08648 1/20 0.40
CHRNB1 P11230 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
CHRND Q07001 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL911806 1.00 FFAR4 (0.46) FFAR4SLC6A4SLC6A2SLC6A3PTGS1
SCHEMBL910604 0.89 SLC6A4 (0.54) FFAR4SLC6A4SLC6A2SLC6A3
SCHEMBL910602 0.89 SLC6A4 (0.54) FFAR4SLC6A4SLC6A2SLC6A3
SCHEMBL912054 0.79 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3
SCHEMBL912056 0.79 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3
Trifluoroacetic Acid SCHEMBL20958475 0.78 SLC6A4 (0.56) SLC6A4SLC6A2SLC6A3
Trifluoroacetic Acid SCHEMBL20958441 0.78 SLC6A4 (0.76) SLC6A4SLC6A2SLC6A3
Trifluoroacetic Acid SCHEMBL20958440 0.78 SLC6A4 (0.76) SLC6A4SLC6A2SLC6A3
SCHEMBL911256 0.77 SLC6A4 (0.57) SLC6A4SLC6A2SLC6A3
SCHEMBL911257 0.77 SLC6A4 (0.57) SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868017-B2 9-azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2011-01-11 US disclosed
EP-1934212-A1 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-06-25 EP disclosed
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2007-05-17 US disclosed
WO-2007039563-A1 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives AZI2, TPMT, TET3 FFAR4 2599/4885SLC6A4 1776/4885SLC6A2 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.